Heart Failure in WomenA Need for Prospective Data
Eileen M. Hsich, MD*, ,* and
Ileana L. Piña, MD
* Department of Cardiovascular Medicine at the Cleveland Clinic, Cleveland, Ohio
Case Western Reserve University/Louis Stokes VA Medical Center, Cleveland, Ohio
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Curves for All-Cause Mortality in the CHARM Study
Kaplan-Meier curves for all-cause mortality in the CHARM (Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity) study for women and men with heart failure on the basis of the presence or absence of an ischemic cardiomyopathy. Adapted from O'Meara et al. (5).
|
|
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Adjusted Predicted Mortality
Adjusted predicted mortality in women with heart failure and impaired systolic function on the basis of peak oxygen consumption (VO2) and the presence or absence of coronary artery disease (CAD). Adapted from Hsich et al. (14).
|
|
|
